Discordance between GCIG CA-125 progression and RECIST progression in the CALYPSO trial of patients with platinum-sensitive recurrent ovarian cancer.

Journal Information

Full Title: Br J Cancer

Abbreviation: Br J Cancer

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Neoplasms

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Competing interests D. S. Zebic reports honoraria from Merck. A. Tjokrowidjaja reports research funding (institution) from AZ, support for attending meetings from GSK. K. E. Francis reports funding from BMS, support for attending educational meeting. M. Friedlander reports consulting fees from Novartis, AstraZeneca, MSD, GSK; honoraria from AstraZeneca, GSK, MSD; grants (institution) from AstraZeneca, Novartis, Beigene; participation on a Data Safety Monitoring Board or Advisory Board for AGITG. V. Gebski reports no conflict of interest. A. Lortholary reports participation on Advisory Board for AstraZeneca, MSD Tesaro; honoraria from Clovis Oncology, Roche; congress participation for Novartis, Pfizer, MAD, Lilly, Roche; member of CS3 sein UNICANCER. F. Joly reports participation on Advisory Board for GSK, AstraZeneca, Clovic, Seagen, Janssen, ESAI, Bayer, Viatris, MSD, Ipsen, Amgen, Astellas; honoraria from GSK, Bayer, ESAI, MSD; research funding (personal) from AstraZeneca, GSK; participation member for ASCO, GCIG; congress travel fees from GSK, MSD, ESAI, Ipsen. A. Hasenburg reports honoraria from AstraZeneca, Celgen, GSK, LEO Pharma, MedConcept GmbH, Med update GmbH, Medicultus, Pfizer, Promedicis GmbH, Softconsult, Roche Pharma AG, Streamedup GmbH, Tesaro Bio Germany GmbH; participation on Advisory Board for AstraZeneca, GSK, LEO Pharma, PharmaMar, Promedicis GmbH, Roche Pharma AG, Tesaro Bio Germany GmbH, MSD Sharp&Dohme GmbH. M. Mirza reports participation Data Safety Monitoring Board or Advisory Board for Astra Zeneca, Biocad, GSK, Karyopharm, Merck, Roche, Zailab; honoraria from Astra Zeneca, GSK; research funding (institution) from Apexigen, AstraZeneca, Deciphera (trial chair), GSK, and Ultimovacs; and personal financial interest in Karyopharm (stocks/shares, member of Board of Directors). U. Denison reports no conflict of interest. S. C. Cecere reports honoraria from AstraZeneca, MSD, Pharmamar. A. Ferrero reports honoraria from AstraZeneca, MSD, GlaxoSmithKline, Clovis; participation Data Safety Monitoring Board or Advisory Board for AstraZeneca, MSD. E. Pujade-Lauraine reports honoraria (personal) from AstraZeneca, GSK, Agenus; grants (institution) from AstraZeneca, Merck; participation on Advisory Board or Data Safety Monitoring Board for Incyte, Roche, Pfizer; and is an employee of ARCAGY GINECO research. C.K. Lee reports honoraria from AstraZeneca, Roche, Amgen, GSK, Merck KGA, Novartis, Pfizer, Janssen; grants (institution) from AstraZeneca, Roche, Amgen, Merck KGA; support for attending meetings from AstraZeneca."

Evidence found in paper:

"Funding Open Access funding enabled and organized by CAUL and its Member Institutions."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025